Non-Vitamin K antagonist oral anticoagulants (NOAC): Considerations on once- vs. twice-daily regimens and their potential impact on medication adherence

Europace

Volumn 17, Issue 8, 2015, Pages 1317-1318

  Heidbuchel, Hein ^a   Vrijens, Bernard ^b  

^a HASSELT UNIVERSITY   (Belgium)

^b MWV Healthcare   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; CARDIOVASCULAR AGENT; ANTICOAGULANT AGENT;

ATRIAL FIBRILLATION; DRUG CONCENTRATION; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; HUMAN; LETTER; MAXIMUM PLASMA CONCENTRATION; MEDICATION COMPLIANCE; MINIMUM PLASMA CONCENTRATION; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; DRUG ADMINISTRATION; THROMBOEMBOLISM;

ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MEDICATION ADHERENCE; THROMBOEMBOLISM;

EID: 84939603631     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euv124     Document Type: Letter

References (7)

1. Adler M, Nagler M. Adherence to treatment with non-vitamin K antagonist anticoagulants: once-vs. twice-daily regimens. Europace 2015;17:1316
2. Baker WL, Coleman CI. Medication adherence and non-vitamin K antagonist oral anticoagulants: what do we really know? Europace 2015;17:1316-7
3. Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once-vs. twicedaily regimens and their potential impact on medication adherence. Europace 2015;17:514-23
4. Coleman CI, Roberts MS, Sobieraj DM, Lee S, Alam T, Kaur R. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin 2012;28:669-80
5. Vrijens B, Urquhart J. Methods for measuring, enhancing, and accounting for medication adherence in clinical trials. Clin Pharmacol Ther 2014;95: 617-26
6. MueckW, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK et al. Population pharmacokinetics and pharmacodynamics of once-and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008;100:453-61
7. Flexner C, Tierney C, Gross R, Andrade A, Lalama C, Eshleman SH et al. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis 2010;50:1041-52.